Standard BioTools Announces NGS Library Preparation as an Upgrade on the X9 High-Throughput Genomics System
18 Maio 2023 - 8:30AM
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose
– Unleashing tools to accelerate breakthroughs in human health –
today announced the launch of NGS library preparation functionality
on the X9™ High-Throughput Genomics System. For the first time
ever, customers can perform real-time PCR and next-generation
sequencing (NGS) library prep applications on a single benchtop
system to support discovery through screening.
The X9 System, powered by proprietary microfluidics technology,
delivers operational efficiency by enabling customers to generate
up to 384 sequencing-ready barcoded libraries daily while reducing
reagent and plastics use by nearly 100x relative to traditional
plate-based protocols. This eliminates the need for bulky liquid
handling robots that consume limited lab space, require custom
configuration and use larger sample and reagent volumes.
“The newest X9 System showcases our commitment to our customers,
ensuring that we are addressing their challenges and providing
robust solutions that support and accelerate their research,” said
Michael Egholm, PhD, President and Chief Executive Officer of
Standard BioTools. “This compact instrument improves a lab’s
efficiency with walk-away automation that can produce NGS-ready
libraries in about eight hours and qPCR data in under two
hours.”
Customers can create their NGS libraries and assess their
quality and quantity in a single workflow ahead of expensive NGS
runs. This unified approach has the potential to catch any errors
earlier and ensure that samples will not go to waste.
To learn more about the X9 System, watch the video and visit our
website.
Use of Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, among others, guidance, including related to
revenues, margin, and operating expenses, and statements regarding
future financial performance and expectations, operational and
strategic plans, deployment of capital, our cash runway and
sufficiency of cash resources, potential M&A activity, and
expectations with respect to our restructuring plans (including
expense reduction activities). Forward-looking statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from currently anticipated results,
including but not limited to risks that we may not realize expected
cost savings from the restructuring, including the anticipated
decrease in operational expenses, at the levels we expect; possible
restructuring and transition-related disruption, including through
the loss of customers, suppliers, and employees and adverse impacts
on our development activities and results of operation;
restructuring activities, including our subleasing plans, customer
and employee relations, management distraction, and reduced
operating performance; risks that internal and external costs
required for ongoing and planned activities may be higher than
expected, which may cause us to use cash more quickly than we
expect or change or curtail some of our plans, or both; risks that
our expectations as to expenses, cash usage, and cash needs may
prove not to be correct for other reasons such as changes in plans
or actual events being different than our assumptions; changes in
Standard BioTools’ business or external market conditions;
challenges inherent in developing, manufacturing, launching,
marketing, and selling new products; interruptions or delays in the
supply of components or materials for, or manufacturing of,
Standard BioTools products; reliance on sales of capital equipment
for a significant proportion of revenues in each quarter; seasonal
variations in customer operations; unanticipated increases in costs
or expenses; uncertainties in contractual relationships; reductions
in research and development spending or changes in budget
priorities by customers; uncertainties relating to Standard
BioTools’ research and development activities, and distribution
plans and capabilities; potential product performance and quality
issues; risks associated with international operations;
intellectual property risks; and competition. Information on these
and additional risks and uncertainties and other information
affecting Standard BioTools’ business and operating results is
contained in its Annual Report on Form 10-K for the year ended
December 31, 2022, and in its other filings with the Securities and
Exchange Commission. These forward-looking statements speak only as
of the date hereof. Standard BioTools disclaims any obligation to
update these forward-looking statements except as may be required
by law.
About Standard BioTools Inc. Standard
BioTools Inc. (Nasdaq:LAB), previously known as Fluidigm
Corporation, is driven by a bold purpose – Unleashing tools to
accelerate breakthroughs in human health. Standard BioTools
has an established portfolio of essential, standardized
next-generation technologies that help biomedical researchers
develop medicines faster and better. As a leading solutions
provider, the company provides reliable and repeatable insights in
health and disease using its proprietary mass cytometry and
microfluidics technologies, which help transform scientific
discoveries into better patient outcomes. Standard BioTools works
with leading academic, government, pharmaceutical, biotechnology,
plant and animal research, and clinical laboratories worldwide,
focusing on the most pressing needs in translational and clinical
research, including oncology, immunology, and immunotherapy. Learn
more at www.standardbio.com or connect with us on Twitter®,
Facebook®, LinkedIn, and YouTube™. Standard BioTools, the Standard
BioTools logo, Fluidigm, the Fluidigm logo, “Unleashing tools to
accelerate breakthroughs in human health,” Hyperion, Hyperion XTi,
XTi, and X9 are trademarks and/or registered trademarks
of Standard BioTools Inc. or its affiliates in the
United States and/or other countries. All other trademarks are
the sole property of their respective owners. Standard
BioTools products are provided for Research Use
Only. Not for use in diagnostic procedures.
Available Information Standard
BioTools uses its website (standardbio.com), investor site
(investors.standardbio.com), corporate Twitter account
(@Standard_BioT), Facebook page (facebook.com/StandardBioT), and
LinkedIn page (linkedin.com/company/standard-biotools) as channels
of distribution of information about its products, its planned
financial and other announcements, its attendance at upcoming
investor and industry conferences, and other matters. Such
information may be deemed material information, and Standard
BioTools may use these channels to comply with its disclosure
obligations under Regulation FD. Therefore, investors should
monitor Standard BioTools’ website and its social media accounts in
addition to following its press releases, SEC filings,
public conference calls, and webcasts.
Media Contact:Theresa
Royermedia@standardbio.com
Investor Contacts:Scott Greenstone,
CFAir@standardbio.com
Peter DeNardoir@standardbio.com
Standard BioTools (NASDAQ:LAB)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Standard BioTools (NASDAQ:LAB)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024